Standard
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. / van Herpen, Carla M L; Lassen, Ulrik; Desar, Ingrid M E; Brown, Kathryn H; Marotti, Marcelo; de Jonge, Maja J A.
In:
Anti-Cancer Drugs, Vol. 24, No. 2, 2013, p. 204-11.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
van Herpen, CML
, Lassen, U, Desar, IME, Brown, KH, Marotti, M & de Jonge, MJA 2013, '
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment',
Anti-Cancer Drugs, vol. 24, no. 2, pp. 204-11.
https://doi.org/10.1097/CAD.0b013e32835bd1d2APA
van Herpen, C. M. L.
, Lassen, U., Desar, I. M. E., Brown, K. H., Marotti, M., & de Jonge, M. J. A. (2013).
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
Anti-Cancer Drugs,
24(2), 204-11.
https://doi.org/10.1097/CAD.0b013e32835bd1d2Vancouver
van Herpen CML
, Lassen U, Desar IME, Brown KH, Marotti M, de Jonge MJA.
Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
Anti-Cancer Drugs. 2013;24(2):204-11.
https://doi.org/10.1097/CAD.0b013e32835bd1d2Author
van Herpen, Carla M L ; Lassen, Ulrik ; Desar, Ingrid M E ; Brown, Kathryn H ; Marotti, Marcelo ; de Jonge, Maja J A. / Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. In: Anti-Cancer Drugs. 2013 ; Vol. 24, No. 2. pp. 204-11.
Bibtex
@article{7c93854b28954cdfb4f2fbf3e6f12951,
title = "Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment",
author = "{van Herpen}, {Carla M L} and Ulrik Lassen and Desar, {Ingrid M E} and Brown, {Kathryn H} and Marcelo Marotti and {de Jonge}, {Maja J A}",
year = "2013",
doi = "10.1097/CAD.0b013e32835bd1d2",
language = "English",
volume = "24",
pages = "204--11",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams & Wilkins",
number = "2",
}
RIS
TY - JOUR
T1 - Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment
AU - van Herpen, Carla M L
AU - Lassen, Ulrik
AU - Desar, Ingrid M E
AU - Brown, Kathryn H
AU - Marotti, Marcelo
AU - de Jonge, Maja J A
PY - 2013
Y1 - 2013
U2 - 10.1097/CAD.0b013e32835bd1d2
DO - 10.1097/CAD.0b013e32835bd1d2
M3 - Journal article
C2 - 23197081
VL - 24
SP - 204
EP - 211
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
SN - 0959-4973
IS - 2
ER -
